Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
Focal salvage brachytherapy
High dose rate brachytherapy
Local recurrence
Prostate cancer
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
03
03
2020
revised:
24
03
2020
accepted:
25
03
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Isolated local recurrence of prostate cancer following primary radiotherapy or brachytherapy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence of high quality evidence to support this approach. Men with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an institutional database. Univariable analysis was performed to evaluate the relationship between patient, disease and treatment factors with biochemical progression free survival (bPFS). 43 patients were eligible for evaluation. Median follow up duration was 26 months (range 1-60). Median bPFS was 35 months (95% confidence interval 25.6-44.4). Kaplan-Meier estimates for bPFS at 1, 2 and 3 years post salvage were 95.2%, 70.6% and 41.8% respectively. On univariable Cox regression analysis, only nadir PSA was significantly associated with bPFS although the majority of patients were also treated with androgen deprivation therapy. Only one late grade 3 genitourinary toxicity was observed. Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer.
Identifiants
pubmed: 32368626
doi: 10.1016/j.ctro.2020.03.010
pii: S2405-6308(20)30023-9
pmc: PMC7186261
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20-26Informations de copyright
© 2020 The Authors.
Références
Urol Oncol. 2019 Sep;37(9):582-598
pubmed: 31133370
Cancer. 2007 Oct 1;110(7):1485-92
pubmed: 17701957
Radiat Oncol. 2014 Apr 30;9:102
pubmed: 24885287
Technol Cancer Res Treat. 2003 Aug;2(4):339-44
pubmed: 12892517
Urol Oncol. 2014 Jul;32(5):701-6
pubmed: 24629499
Eur Urol Oncol. 2019 Feb;2(1):47-76
pubmed: 30929846
Radiother Oncol. 2016 Apr;119(1):104-10
pubmed: 26897512
Radiother Oncol. 2016 Jun;119(3):411-6
pubmed: 27118583
Radiother Oncol. 2016 Jun;119(3):405-10
pubmed: 27165612
Brachytherapy. 2014 Mar-Apr;13(2):111-6
pubmed: 24373762
J Urol. 2008 Apr;179(4):1368-73; discussion 1373
pubmed: 18289585
Radiother Oncol. 2016 Jan;118(1):122-30
pubmed: 26549865
Brachytherapy. 2018 Mar - Apr;17(2):291-297
pubmed: 29137956
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7
pubmed: 22672747
BJU Int. 2018 May;121(5):781-790
pubmed: 29319928
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33
pubmed: 17084558
Technol Cancer Res Treat. 2017 Dec;16(6):1194-1201
pubmed: 29333958
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):561-567
pubmed: 30244878
Brachytherapy. 2017 Mar - Apr;16(2):291-298
pubmed: 28139422
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Brachytherapy. 2014 Jan-Feb;13(1):53-8
pubmed: 24295965
Brachytherapy. 2016 May-Jun;15(3):296-305
pubmed: 26948662
J Urol. 2006 Nov;176(5):2020-4
pubmed: 17070243
Eur Urol. 2015 Jun;67(6):1009-1016
pubmed: 25308970
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44
pubmed: 20138442
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1038-1044
pubmed: 30771408
Eur Urol. 2013 Jan;63(1):125-40
pubmed: 22743165
Radiother Oncol. 2014 Jul;112(1):77-82
pubmed: 24998704
Urology. 1999 Nov;54(5):880-3
pubmed: 10565751
Clin Radiol. 2008 Apr;63(4):387-95
pubmed: 18325358
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343
pubmed: 30312717
Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):537-47
pubmed: 1869452
Brachytherapy. 2017 Nov - Dec;16(6):1091-1098
pubmed: 28838648
J Clin Oncol. 2009 Apr 1;27(10):1537-9
pubmed: 19255300
Brachytherapy. 2010 Apr-Jun;9(2):119-25
pubmed: 19850536
Cancer. 2008 Jan 15;112(2):307-14
pubmed: 18050294
Urol Int. 2013;90(3):294-300
pubmed: 23467122
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9
pubmed: 23474112
Eur Urol. 2015 Jul;68(1):8-19
pubmed: 25454618
J Urol. 1990 Sep;144(3):704-6
pubmed: 2388332
Urology. 1999 Jan;53(1):2-10
pubmed: 9886580
J Contemp Brachytherapy. 2016 Jun;8(3):241-8
pubmed: 27504134
Clin Oncol (R Coll Radiol). 2020 Apr;32(4):259-265
pubmed: 31708350
Eur Urol. 2019 Sep;76(3):284-303
pubmed: 31130434
BJU Int. 2009 Sep;104(5):600-4
pubmed: 19245439
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):568-76
pubmed: 27318423
Prostate. 1993;23(4):283-90
pubmed: 8259342
J Clin Oncol. 2005 Oct 1;23(28):6992-8
pubmed: 16192586
Radiother Oncol. 2019 Dec;141:156-163
pubmed: 31570236
Cancer. 2007 Jul 1;110(1):68-80
pubmed: 17520705